Fractions of porcine cerebral cortex extract separated by molecular weight on a Sephadex C-75 column were
It is an accepted pharmacologic concept that many drugs initially act by binding to effector cell membranes at specific receptor sites. In the brain many of the specific receptor sites are thought to be part of a system that depends on a neurohormone that binds to and activates these specific receptors. "Neurohormone" is used in an all-inclusive sense to mean any grain substance that is released and subsequently alters neural activity. If the benzodiazepines exert their effects by mimicking such a neurohormone, then it should be possible to demonstrate the binding of a radiolabeled benzodiazepine to brain homogenates containing some of the neurohormone's receptors. Workers in at least six independent laboratories have reported
[3H]benzodiazepine binding to brain homogenates (1) (2) (3) (4) (5) (6) , and all have reported a single specific binding site with nonspecific binding of only 10% or less. However, demonstration of binding is not sufficient proof that the binding site is a neurohormone receptor.
Other data lend support to the hypothesis that the benzodiazepine binding site is a neurohormone receptor, possibly located at a synapse. In summary, the binding site displays: high affinity (1), reversibility (6) , stereospecificity (7), ligand specificity (4, (7) (8) (9) (10) , species specificity (11), organ specificity (1), synaptic localization (12) , and increases in specific binding after preincubation, indicating the possible dissociation of an endogenous ligand (2, 13, 14) .
In addition, a large number of nonbenzodiazepine drugs and neurohormones have been shown not to compete for the binding site (7, 10) . Also, the distribution of benzodiazepine binding in the brain does not parallel the distribution of binding of any known drug or neurohormone (1) . Such results indicate that the benzodiazepine binding site is not a receptor for these other substances but leave open the possibility that the benzodiazepines act on an undiscovered neurohormone receptor.
If the benzodiazepines are interacting with a neurohormone
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. (17) . The mixture was centrifuged at 12,000 X g for 20 min at 40C. The pellet was resuspended in the extraction solvents, homogenized in a Sorvall homogenizer, stirred for 12 hr at 4°C, and centrifuged. This procedure was repeated 3 times. The supernatants were combined, flash evaporated or lyophilized, redissolved in 1 M acetic acid, and defatted three times with hexane/ethyl acetate (3:1, vol/vol). The organic layer was washed three times with 1 M acetic acid and the combined aqueous layers were finally lyophilized to give the material for column purification.
The lyophilized material was purified on a 2.5 X 90 cm Sephadex G-75 column. The elution was with 1 M acetic acid that contained 0.01% thiodiglycol and 0.0001% pentachlorophenol (17) ; 20-ml fractions were collected.
Hydrolysis and Trypsin Digestion of Active Brain Fractions. The hydrolysis of the active fractions was carried out with 6 M HC1 according to Stuart and Young (18) . Trypsin digestion was carried out in 0.1 M K phosphate buffer, pH 7.5, by incubation with active fraction at 25°C for 60 min. The trypsin was 6320 Neurobiology: Colello et al. subsequently inactivated by incubating at 100'C for 15 min before addition to the binding assay. This heat treatment did not affect the activity of undigested brain fractions.
Binding Assay. Sprague-Dawley rats (300400 g) were decapitated and the brain (minus the cerebellum) was rapidly removed. The brains were homogenized in 10 vol of ice-cold 0.1 M K phosphate buffer, pH 7.05. The homogenate was centrifuged at 500 X g for 10 min to remove large particulate matter. The 500 X g supernatant was centrifuged at 12,000 X g. The 12,000 X g pellet was resuspended in the same phosphate buffer to a protein concentration of 1 mg/ml, determined according to Lowry et al. (19) Fig. 4 . This causes the two semi-logarithmic S--shaped curves to overlap at the 2 nM unlabeled flunitrazepam point and allows their slopes to be compared. The inset of Fig.  5 shows the curves theoretically expected for this type of plot with a competitive inhibitor and a substrate inhibitor according to Webb (22) . A substrate inhibitor should produce a steeper rise in i than a competitive inhibitor (22) . The main plot in Fig.  5 shows that the BCF-I curve shows no hint of a steeper rise and is nearly identical to the unlabeled flunitrazepam curve. The highest concentration of BCF-I, which was near saturation, only produced a 70% (i = 0.7) inhibition of binding. Further purification should result in 100% inhibitory concentrations.
Thermal Stability, Trypsin Digestion, and Acid Hydrolysis of BCF-I. Table 1 shows that BCF-I is thermally stable, but it loses its inhibitory activity after tryp drolysis. While heating at 1000C for tivated trypsin, it had no effect on no] loss of activity after trypsin digestion oi the presence of peptide bonds in the as molecule(s).
Discussion. We have attempted porcine brain that competitively ining. Inhibitory activity was foun and a low (BCF-II) Mr fraction from fractions. BCF-I proved to be some BCF-II and was studied further.
We tried to use a method of express that was as accurate and universally Percent inhibition of control binding grams of dry fractional residue added was used as the quantitative measur Although inhibitor molarity would h express potency it was felt that mistak introduce too much error into molari ,duced by an enzyme that degraded the receptor (e.g., a protease), was not indicated in a double-reciprocal plot that showed inhibition similar to that of unlabeled flunitrazepam (by definition a competitive inhibitor). Substrate inhibition, which in a double-reciprocal plot can appear similar to competitive inhibition, was not indicated in a fractional inhibition plot of 8 7 6 various concentrations of unlabeled flunitrazepam or BCF-I.
23
63 BCF-I (0.5 mg) was incubated with 2% trypsin at 250C for 60 min followed by incubation at 1001C for 15 min to inactivate the trypsin before addition to the binding assay. § BCF-I (0.5 mg) was heated overnight at 100'C in 6 M HCL Most of the HCl was then drawn off over NaOH crystals under reduced pressure. Any remaining HOl was carefully neutralized with dilute NaOH to pH 7.0 before addition to the binding assay.
